Skip to Content

Retisert Approval History

  • FDA approved: Yes (First approved April 8th, 2005)
  • Brand name: Retisert
  • Generic name: fluocinolone acetonide
  • Dosage form: Intravitreal Implant
  • Company: Bausch & Lomb
  • Treatment for: Uveitis

Retisert (fluocinolone acetonide) intravitreal implant is indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.

Development History and FDA Approval Process for Retisert

Apr  8, 2005Approval Retisert Bausch & Lomb - Treatment for Chronic Non-Infectious Uveitis

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.